LAY

N-acetyl-L-leucine

Created:2015-01-22
Last modified:  2024-09-27

Find related ligands:

Chemical Details

Formal Charge0
Atom Count27
Chiral Atom Count1
Bond Count26
Aromatic Bond Count0
2D diagram of LAY

Chemical Component Summary

NameN-acetyl-L-leucine
Systematic Name (OpenEye OEToolkits)(2S)-2-acetamido-4-methyl-pentanoic acid
FormulaC8 H15 N O3
Molecular Weight173.21
TypeL-PEPTIDE LINKING

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01O=C(NC(C(=O)O)CC(C)C)C
SMILESCACTVS3.385CC(C)C[CH](NC(C)=O)C(O)=O
SMILESOpenEye OEToolkits1.7.6CC(C)CC(C(=O)O)NC(=O)C
Canonical SMILESCACTVS3.385 CC(C)C[C@H](NC(C)=O)C(O)=O
Canonical SMILESOpenEye OEToolkits1.7.6 CC(C)C[C@@H](C(=O)O)NC(=O)C
InChIInChI1.03 InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1
InChIKeyInChI1.03 WXNXCEHXYPACJF-ZETCQYMHSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB16956 
NameL-Acetylleucine
Groups
  • approved
  • investigational
DescriptionLevacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo.[A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine, after which animal studies showed that the L-enantiomer (i.e. levacetylleucine) has potential clinical benefits compared to the racemic mixture.[A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]
Synonyms
  • Acetyl-l-leucine
  • (s)-2-acetamido-4-methylpentanoic acid
  • N-Acetyl-Leucine
  • N-acetylleucine
  • L-leucine, n-acetyl-
Brand Names
  • Aqneursa
  • Brand name
IndicationLevacetylleucine is indicated for the treatment of neurological symptoms of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.[L51439]
Categories
  • Amino Acids
  • Amino Acids, Branched-Chain
  • Amino Acids, Essential
  • Amino Acids, Peptides, and Proteins
  • BCRP/ABCG2 Inhibitors
CAS number1188-21-2

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Solute carrier family 22 member 6MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR...unknownsubstrate,inhibitor
Organic anion transporter 3MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...unknownsubstrate,inhibitor
ATP-dependent translocase ABCB1MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...unknowninhibitor
Broad substrate specificity ATP-binding cassette transporter ABCG2MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...unknowninhibitor
Bile salt export pumpMSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQL...unknowninhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 70912
ChEMBL CHEMBL56021
ChEBI CHEBI:17786
CCDC/CSD ACLLEU01